Baillie Gifford & Co
BBIO icon

Baillie Gifford & Co’s BridgeBio Pharma BBIO Stock Holding History

Baillie Gifford & Co’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-499,889
Closed -$4.97M – 488
2022
Q3 		$4.97M Buy
499,889
+15,412
+3% +$160K 0.01% 237
2022
Q2 		$4.4M Sell
484,477
-57,414
-11% -$480K ﹤0.01% 241
2022
Q1 		$5.5M Buy
541,891
+52,170
+11% +$535K ﹤0.01% 250
2021
Q4 		$8.17M Buy
489,721
+23,845
+5% +$1.01M ﹤0.01% 252
2021
Q3 		$21.8M Buy
465,876
+45,984
+11% +$2.46M 0.01% 220
2021
Q2 		$25.6M Buy
419,892
+107,247
+34% +$6.12M 0.01% 218
2021
Q1 		$19.3M Buy
312,645
+194,113
+164% +$12.7M 0.01% 227
2020
Q4 		$8.43M Buy
118,532
+58,063
+96% +$2.8M ﹤0.01% 224
2020
Q3 		$2.27M Buy
60,469
+54,660
+941% +$1.72M ﹤0.01% 230
2020
Q2 		$189K Buy
5,809
+3,109
+115% +$94.7K ﹤0.01% 237
2020
Q1 		$78K Buy
+2,700
New +$83.7K ﹤0.01% 220

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Baillie Gifford & Co's BBIO Position: Q4 2022 in Review

Baillie Gifford & Co sold out of BridgeBio Pharma (BBIO) in Q4 2022, closing a stake of 499,889 shares — an estimated $4.97M sold.

Baillie Gifford & Co first reported a position in BBIO in Q1 2020 and held it in 11 quarters. The position peaked at $25.6M in Q2 2021. 179 funds tracked by Wall St. Rank hold BBIO as of Q4 2022.

  • Baillie Gifford & Co reported no remaining BridgeBio Pharma position as of Q4 2022 after selling out during the quarter.
  • Baillie Gifford & Co sold 499,889 BridgeBio Pharma shares in Q4 2022, an estimated $4.97M.
  • Baillie Gifford & Co first reported a position in BridgeBio Pharma in Q1 2020 and held it in 11 quarters.
  • Baillie Gifford & Co's BridgeBio Pharma position peaked at $25.6M in Q2 2021.
  • 179 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2022.

Based on Baillie Gifford & Co's 13F filing for Q4 2022, filed 24 Jan 2023.